Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple injection timing reduce bleeding after skin cancer surgery?

NCT ID NCT07807371

Disease control Sponsor: The Cooper Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether giving tranexamic acid (TXA) before or after the reconstruction step of Mohs surgery better reduces bleeding. Mohs surgery removes skin cancer layer by layer, and TXA is already used to lessen bleeding. The study includes 500 adults having Mohs with a same-day closure, flap, or graft, with extra focus on those taking blood thinners or having complex repairs. Researchers will track bleeding events within 48 hours and wound complications within 30 days to see if one timing is not worse than the other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid (TXA) injection
What this could lead to
If it works, this could help surgeons choose the best time to give TXA during Mohs surgery, reducing bleeding complications and improving recovery for patients at higher risk.
What could go wrong
This is an early-stage trial, and the results may not apply to all patients. TXA can rarely cause allergic reactions or blood clots, though these risks are low.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older. 2. Undergoing MMS at a participating site with a planned same-day linear closure, flap reconstruction, or graft reconstruction. 3. Willing and able to provide written informed consent. 4. Able to participate in standard postoperative follow-up and to be reached if follow-up clarification is required. Exclusion Criteria: 1. Known allergy or hypersensitivity to TXA. 2. Active deep-vein thrombosis, pulmonary embolism, stroke, myocardial infarction, or other active thromboembolic event at the time of surgery. 3. Thromboembolic event within the previous 3 months. 4. Systolic blood pressure greater than 200 mmHg at the time of surgery. 5. Pregnancy or breastfeeding. 6. Planned second-intention healing without reconstruction. 7. History of seizures or current medication judged by the investigator to materially lower seizure threshold. 8. Reported serum creatinine of 5 mg/dL or greater. 9. Unable to complete the 48-hour outcome assessment or standard postoperative follow-up. 10. Prior enrollment in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.